I næsten alle de kliniske studier, der er gennemført af seglcellesygdom, reducerede hydroxycarbamid hyppigheden af vasookklusive episoder med 66% til 80% hos børn og voksne.
In nearly all clinical studies conducted in Sickle Cell Syndrome, hydroxycarbamide reduced the frequency of vaso-occlusive episodes by 66% to 80%, in children and in adults.